Research
Hormonal
The hyperinsulinemic euglycemic clamp is the gold standard method for quantifying insulin sensitivity in vivo, offering high reproducibility and the ability to distinguish hepatic from peripheral resistance.
The hyperinsulinemic euglycemic clamp is the most accurate way to measure insulin sensitivity and is the research gold standard. However, due to its complexity and cost, it is reserved for research. Clinicians use simpler, less accurate surrogate tests for routine patient care.
StrongSupportsVERY_HIGH confidence
It is regarded as being the gold standard to quantify insulin sensitivity in vivo... The euglycemic hyperinsulinemic clamp is presently the most widely used method in the research setting and it is highly reproducible, with CV as low as 6.3-0.9%.
Why this rating
Described as the 'gold standard' with low coefficient of variation and extensive validation in literature.
Source
Evaluation of Insulin Sensitivity in Clinical Practice and in Research Settings
Lais U. Monzillo et al. · Nutrition Reviews · 2003
DOI 10.1301/nr.2003.dec.397-412
narrative_reviewCited 258×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Insulin resistance is the core metabolic abnormality in type 2 diabetes and is directly related to the risk of developing atherosclerosis and cardiovascular disease.Good
- Lifestyle modifications can improve insulin sensitivity and delay progression to type 2 diabetes, although quantitative evaluation of insulin sensitivity was often missing from early trials.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →